ATX-MS-1467 in Multiple Sclerosis

Summary

This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of any such effects.

Timeline

Start

2014-02-28

Primary completion

2016-04-30

Completion

2016-04-30

Drugs

Indications